Vidofludimus hemicalcium (4sc-101, SC12267) is an orally active compound that acts as a dihydroorotate dehydrogenase (DHODH) inhibitor and serves as a novel modulator of the farnesoid X receptor (FXR). This immunomodulatory agent is utilized in the research of autoimmune disorders, including inflammatory bowel disease (IBD), and is explored for its potential in fatty liver disease research through FXR targeting.
Molecular Weight:
375.4
CAS Number:
[1354012-90-0]
Formula:
C20H18FNO4.1/2Ca
Target:
Others|||Interleukin|||FXR|||Dehydrogenase
T70899
* VAT and and shipping costs not included. Errors and price changes excepted
